Aclaris Therapeutics (NASDAQ:ACRS) Releases Earnings Results, Misses Estimates By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01), Zacks reports. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%.

Aclaris Therapeutics Stock Down 7.2 %

NASDAQ:ACRS traded down $0.15 during trading hours on Thursday, reaching $1.95. The company had a trading volume of 638,470 shares, compared to its average volume of 769,210. The stock has a 50-day moving average of $2.47 and a two-hundred day moving average of $2.15. Aclaris Therapeutics has a one year low of $0.95 and a one year high of $5.17. The firm has a market capitalization of $139.15 million, a PE ratio of -3.75 and a beta of 0.50.

Analyst Ratings Changes

A number of analysts have recently issued reports on ACRS shares. Piper Sandler upgraded Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $3.00 to $13.00 in a research report on Monday, November 18th. Cantor Fitzgerald upgraded Aclaris Therapeutics to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, December 23rd. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. Finally, Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics currently has an average rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.